Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study

Publication date: Available online 20 October 2018Source: Journal of Clinical NeuroscienceAuthor(s): Aaron E. Miller, Xianhao Xu, Richard Macdonell, Steve Vucic, Philippe Truffinet, Myriam Benamor, Karthinathan Thangavelu, Mark S. FreedmanAbstractIn the phase 3 TOWER (NCT00751881) study, teriflunomide 14 mg significantly reduced annualized relapse rate (ARR) and risk of 12-week confirmed disability worsening (12-w CDW) vs placebo in patients with relapsing forms of MS (RMS). The TOWER population included an appreciable proportion of Asian patients. Reductions in ARR and 12-w CDW associated with teriflunomide 14 mg were comparable between the Asian and overall populations, as were the rates for adverse events and serious adverse events, with no new or unexpected safety findings. These observations provide further evidence to support the clinical benefits and safety profile of teriflunomide in a broad range of patients with RMS.
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research

Related Links:

In multiple sclerosis (MS), half of affected people are unemployed within 10  years of diagnosis. The aim of this study was to assess the economic impact of MS in adult subjects with relapsing-remitting MS (RRM...
Source: BMC Public Health - Category: Consumer Health News Authors: Tags: Research article Source Type: research
Authors: De Giglio L, Grimaldi AE, Fubelli F, Marinelli F, Pozzilli C Abstract INTRODUCTION: Decades of pharmacological research in Multiple Sclerosis (MS) led to the development of therapeutic Monoclonal Antibodies (MAbs) with many different mechanisms of action (MoA), potentially able to improve disability outcome but also determining a more complex management of patients. Areas covered: When clinicians select MS treatments, they should consider adverse events (AEs) on individual basis to minimize patients' risks. Some AEs are common and can be easily handled, but rare complications should also be taken into account...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
Authors: van Mastrigt GA, Evers SM, Heerings M, Visser LH, Ruimschotel RP, Hussaarts A, Duyverman L, Valkenburg-Vissers J, Cornelissen J, Bos M, van Droffelaar M, Jongen PJ Abstract AIMS: This trial-based economic evaluation (EE) assesses from a societal perspective the cost-effectiveness of an intensive 3-day cognitive theory-based intervention (CDT), compared to care-as-usual, in patients with relapsing remitting multiple sclerosis (RRMS) and low disability (Expanded Disability Status Scale [EDDS] score
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
ConclusionsSince anti-MOG+ patients can have a multiphasic disease course and accumulate disability over time, high degree of suspicion and early diagnosis are of critical importance for treatment decision-making in clinical practice.AimThe aim of this case report is to enhance focus on an emerging disease spectrum among acquired CNS demyelinating disorders.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
This study was conducted retrospectively examining the patient records of our MS Clinic. The patient records in 1996 were compared to those in 2016.MethodsDemographic data, duration of disease, time to diagnosis, course of the disease, EDSS scores, and whether or not patients used DMTs were recorded in both 1996 and 2016.ResultsThe mean frequency of visits were significantly higher in 1996 compared to 2016 (p=0.003). There were significantly more number of patients with CIS (p=0.004) and SPMS (p=0.001) in 1996; however, significantly less number of patients with RRMS (p
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
This study aims to evaluate the gene expression of these factors in multiple sclerosis (MS) patients compared to healthy individuals and correlate them with the severity of MS. MATERIALS AND METHODS: Sixty participants, including 30 patients with MS and 30 healthy controls were studied. The expression of PIAS1 and PIAS2 genes in peripheral blood samples of all participants was measured by real-time PCR. The severity of MS was evaluated using the Expanded Disability Status Scale (EDSS). Finally, we evaluated the correlation between the expression of PIAS1 and PIAS2 genes with disease severity. RESULTS: The expressio...
Source: Journal of Immunoassay and Immunochemistry - Category: Biochemistry Tags: J Immunoassay Immunochem Source Type: research
CONCLUSIONS: Persons of older age, progressive MS, and higher disability status spend prolonged, uninterrupted periods of time sedentary. Such results highlight the need for targeted interventions in sub-populations of MS that reduce time spent sedentary and break up the pattern of sedentary behaviour. Implications for Rehabilitation Sedentary behaviour is highly prevalent in multiple sclerosis and may be associated with comorbid conditions. The majority of research on sedentary behaviour in multiple sclerosis has been derived from self-report instruments that only measure the volume of sitting time per day. This study ind...
Source: Disability and Rehabilitation - Category: Rehabilitation Authors: Tags: Disabil Rehabil Source Type: research
AbstractTeriflunomide (Aubagio®) is a disease-modifying immunomodulatory drug with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydro-orotate dehydrogenase, with consequent inhibition of de novo pyrimidine synthesis and reduced lymphocyte proliferation. Based on extensive evidence from randomized controlled trials (RCTs) and the real-world setting, oral teriflunomide is an effective and generally well tolerated treatment in patients with relapsing multiple sclerosis (MS), with these benefits maintained during long-term treatment ( ≥ 10 years) and no new...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
ConclusionMore data is needed to determine long-term disease modifying effects of corticosteroids. The findings of this study suggest that, perhaps, regular pulse glucocorticoid treatment may have important long-term consequences (beneficial) for patients with MS and it may achieve the NEDA target. Certainly, the magnitude of the reported effects deserves further investigation in both relapsing and progressive MS populations.
Source: Steroids - Category: Drugs & Pharmacology Source Type: research
Abstract Recent trial studies have shown that omega-3 supplementation can beneficially improve Expanded Disability Status Scale (EDSS) which considered as a gold standard for measuring disability and disease severity in multiple sclerosis (MS) patients as well as reducing neuroinflammation. The present systematic review and meta-analysis aimed to evaluate the effect of omega-3 supplementation on EDSS and cytokines in MS. We performed a systematically search on Pubmed, Scopus and Cochrane Library up to October 2018. Studies were reviewed based on Cochrane handbook and preferred reporting items for systematic review...
Source: CNS and Neurological Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Tags: CNS Neurol Disord Drug Targets Source Type: research
More News: Brain | Disability | Multiple Sclerosis | Neurology | Neuroscience | Study